Literature DB >> 24678776

De novo VHL germline mutation detected in a patient with mild clinical phenotype of von Hippel-Lindau disease.

Xinghua Ding1, Chao Zhang2,3, Jason M Frerich2, Anand Germanwala2, Chunzhang Yang2, Russell R Lonser4, Ying Mao1, Zhengping Zhuang2, Mingguang Zhang1.   

Abstract

Von Hippel-Lindau (VHL) disease is an autosomal dominant multiorgan tumor syndrome caused by a germline mutation in the VHL gene. Characteristic tumors include CNS hemangioblastomas (HBs), endolymphatic sac tumors, renal cell carcinomas, pheochromocytomas, and pancreatic neuroendocrine tumors. Sporadic VHL disease with a de novo germline mutation is rare. The authors describe a case of multiple CNS HBs in a patient with a heterozygous de novo germline mutation at c.239G>T [p.S80I] of VHL. This is the first known case of a sporadic de novo germline mutation of VHL at c.239G>T. Clinicians should continue to consider VHL disease in patients presenting with sporadic CNS HBs, including those without a family history, to confirm or exclude additional VHL-associated visceral lesions.

Entities:  

Keywords:  HB = hemangioblastoma; RCC = renal cell carcinoma; VHL = von Hippel-Lindau; de novo mutation; hemangioblastoma; oncology; pVHL = VHL protein; von Hippel-Lindau disease

Mesh:

Substances:

Year:  2014        PMID: 24678776      PMCID: PMC4749034          DOI: 10.3171/2014.2.JNS131190

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  13 in total

Review 1.  Role of VHL gene mutation in human cancer.

Authors:  William Y Kim; William G Kaelin
Journal:  J Clin Oncol       Date:  2004-12-15       Impact factor: 44.544

Review 2.  VHL disease.

Authors:  Marta Barontini; Patricia L M Dahia
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

3.  VHL mutation analysis in patients with isolated central nervous system haemangioblastoma.

Authors:  Emma R Woodward; Kerry Wall; Joan Forsyth; Fiona Macdonald; Eamonn R Maher
Journal:  Brain       Date:  2007-01-29       Impact factor: 13.501

Review 4.  von Hippel-Lindau disease: a clinical and scientific review.

Authors:  Eamonn R Maher; Hartmut Ph Neumann; Stéphane Richard
Journal:  Eur J Hum Genet       Date:  2011-03-09       Impact factor: 4.246

5.  Family history of von Hippel-Lindau disease was uncommon in Chinese patients: suggesting the higher frequency of de novo mutations in VHL gene in these patients.

Authors:  Pengjie Wu; Ning Zhang; Xi Wang; Xianghui Ning; Teng Li; Dingfang Bu; Kan Gong
Journal:  J Hum Genet       Date:  2012-02-23       Impact factor: 3.172

6.  Detection of a germline mutation and somatic homozygous loss of the von Hippel-Lindau tumor-suppressor gene in a family with a de novo mutation. A combined genetic study, including cytogenetics, PCR/SSCP, FISH, and CGH.

Authors:  H J Decker; C Neuhaus; A Jauch; M Speicher; T Ried; M Bujard; H Brauch; S Störkel; M Stöckle; B Seliger; C Huber
Journal:  Hum Genet       Date:  1996-06       Impact factor: 4.132

7.  Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene.

Authors:  F M Richards; S J Payne; B Zbar; N A Affara; M A Ferguson-Smith; E R Maher
Journal:  Hum Mol Genet       Date:  1995-11       Impact factor: 6.150

8.  Germline mutations in the von Hippel-Lindau disease (VHL) gene in mainland Chinese families.

Authors:  Jin Zhang; Yiran Huang; Jiahua Pan; Dongming Liu; Lixin Zhou; Wei Xue; Qi Chen; Baijun Dong; Hanqing Xuan
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-30       Impact factor: 4.553

9.  Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease.

Authors:  Alexander O Vortmeyer; Stephan Frank; Seon-Yong Jeong; Kristy Yuan; Barbara Ikejiri; Youn-Soo Lee; Deb Bhowmick; Russell R Lonser; Reginald Smith; Griffin Rodgers; Edward H Oldfield; Zhengping Zhuang
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

10.  von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells.

Authors:  Deric M Park; Zhengping Zhuang; Ling Chen; Nicholas Szerlip; Irina Maric; Jie Li; Taesung Sohn; Stephanie H Kim; Irina A Lubensky; Alexander O Vortmeyer; Griffin P Rodgers; Edward H Oldfield; Russell R Lonser
Journal:  PLoS Med       Date:  2007-02       Impact factor: 11.069

View more
  2 in total

1.  Von Hippel-Lindau disease type 2 in a Chinese family with a VHL p.W88X truncation.

Authors:  Min Zhang; Jie Wang; Jingjing Jiang; Xiaohui Zhan; Yan Ling; Zhiqiang Lu; Jianming Guo; Xin Gao
Journal:  Endocrine       Date:  2014-07-29       Impact factor: 3.633

Review 2.  The Role of VHL in the Development of von Hippel-Lindau Disease and Erythrocytosis.

Authors:  Petra Hudler; Mojca Urbancic
Journal:  Genes (Basel)       Date:  2022-02-17       Impact factor: 4.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.